Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention
NCT ID: NCT06669520
Last Updated: 2024-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2024-08-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention
NCT01399203
Risk Factors,PREvention and OutComes for CI-AKI in PatientS undErgoing PCI (PRECISE)
NCT07020130
Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients
NCT00651521
Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome
NCT07294911
Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI
NCT05132062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. STEMI symptom onset time \< 12 hours;
3. STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias;
4. High-risk NSTEMI;
5. Emergency PCI;
6. Voluntary informed consent.
Exclusion Criteria
2. Severe chronic kidney disease (defined as estimated glomerular filtration rate \< 20 mL/min per 1.73 m²);
3. Life expectancy \< 1 year;
4. Pregnant or planning to become pregnant;
5. Emergency PCI failure.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Third Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Weihong Jiang, Doctor
Role: backup
Ye Chen, Master
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
K 24655
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.